Business Context and Reporting Period
This Form 8-K was filed by Capricor Therapeutics, Inc. on July 23, 2021. The report discloses a corporate governance event: the election of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of Karimah Es Sabar as a member of the Board of Directors, effective immediately on July 23, 2021. Ms. Es Sabar will receive standard non-employee director compensation. No other material changes to operations or financial status are disclosed in this document.
Outlook, Risks, and Management Commentary
Management Commentary: The Board highlighted Ms. Es Sabar's over 35 years of experience in biopharma leadership, drug development, venture investing, and transactions. Her background includes serving as CEO and Partner at Quark Venture LP and President and CEO at the Centre for Drug Research and Development (CDRD) in Canada. She previously held senior roles at Pasteur Merieux Connaught (Sanofi Pasteur).
Risks and Contingencies: The filing states that Ms. Es Sabar has no relationship with the Company requiring disclosure under Item 404(a) of Regulation S-K. No specific risks or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the effective date of Karimah Es Sabar's board appointment (July 23, 2021).
- Confirm the absence of any undisclosed relationships between the new director and the Company.
- Review the Company's standard non-employee director compensation policy to understand the financial impact of this appointment.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.